Image pharmaphorum Editor Oncology Deep Dive: Oncology 2022 Eradicating cancer is an ambitious goal for oncologists and life science companies around the world. White Papers Sponsored Ensuring successful digital outreach and retention in atopic... Trial organisers face intense competition to find and recruit eligible patients for atopic dermatitis studies. Views & Analysis Medical Informatics and Rare Disease: a bridge between two w... Today’s rare disease landscape comprises of around 7,000 different diseases. Patients From trial design for patients to trial design with patients... At the 2022 Drug Information Association (DIA) annual meeting last week, it was Load more results
Oncology Deep Dive: Oncology 2022 Eradicating cancer is an ambitious goal for oncologists and life science companies around the world.
White Papers Sponsored Ensuring successful digital outreach and retention in atopic... Trial organisers face intense competition to find and recruit eligible patients for atopic dermatitis studies.
Views & Analysis Medical Informatics and Rare Disease: a bridge between two w... Today’s rare disease landscape comprises of around 7,000 different diseases.
Patients From trial design for patients to trial design with patients... At the 2022 Drug Information Association (DIA) annual meeting last week, it was
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
